Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Reyvow (lasmiditan) is indicated for the acute treatment of migraine with or without aura in adults.
• This summary is based on the review of 15 systematic review(s)/meta-analysis(es). ^[1-15]
• Lasmiditan (100 mg and 200 mg) was more effective in achieving pain relief within 2 hours compared to ubrogepant (25 mg and 50 mg) and zavegepant. Lasmiditan 200 mg showed a higher rate of pain freedom at 2 hours than lasmiditan 100 mg.
• For sustained pain relief over 24 hours, rimegepant (75 mg) and ubrogepant (50 mg and 100 mg) were more effective than zavegepant. Lasmiditan 200 mg also provided better sustained pain freedom compared to lasmiditan 100 mg.
• Rimegepant (75 mg) had a higher likelihood of achieving freedom from photophobia within 2 hours compared to ubrogepant (25 mg) and lasmiditan (50 mg). Lasmiditan (100 mg and 200 mg) and rimegepant were equally effective in achieving two-hour freedom from the most bothersome symptom.
• Lasmiditan (100 mg and 200 mg) showed higher efficacy in pain freedom at 2 hours compared to rimegepant (75 mg) and ubrogepant (25 mg and 50 mg), with triptans demonstrating even higher odds ratios for pain freedom at 2 hours compared to lasmiditan, rimegepant, and ubrogepant.
• Adverse events: Lasmiditan exhibited the highest risk of adverse events, including dizziness (RR up to 12.77), somnolence, asthenia, paresthesia, and fatigue, with a higher incidence observed in the 200 mg group compared to the 100 mg group.
• Comparison to other drugs: Rimegepant and ubrogepant had lower rates of adverse events compared to lasmiditan, which also had a higher incidence of central nervous system-related side effects compared to placebo and other drugs.
• Subgroup considerations: In patients with cardiovascular risk factors, lasmiditan 200 mg was associated with a higher risk of adverse events compared to 100 mg.
• There is no population type or subgroup information available in the reviewed studies.